PROGNOSIS OF MYASTHENIA GRAVIS: A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/z1hjdw40Keywords:
Myasthenia gravis, prognosisAbstract
Background: The complex disease progression and treatment challenges affect the overall prognosis in myasthenia gravis (MG) patients. Recent advancements in managing MG have brought about significant progress in attaining complete stable remission as the treatment objective. This study aims to systematically review the prognosis of MG in literatures of the last 10 years.
Methods: This systematic review complied with the PRISMA 2020 standards and focused on full-text English literature published between 2014 and 2024. Articles such as editorials and review papers from the same journal, as well as submissions lacking a DOI, were excluded from consideration. Literature was sourced from online platforms like PubMed and SagePub.
Result: We found 627 articles on PubMed and 810 articles on SagePub. Restricting our search to the past decade (20142024), PubMed presented 425 articles, whereas SagePub presented 309 articles. From these, we selected 5 papers meeting our criteria, with 2 from PubMed and 3 from SagePub.
Conclusion: Significant progress has been achieved in treating MG over the past decade. While some patients experience spontaneous remission, the majority require treatment with steroids or similar drugs. Other treatment modalities such as monoclonal antibody treatment, pulmonary function testing, and thymectomy can be employed to improve the prognosis of MG.
References
Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current Treatment of Myasthenia Gravis. J Clin Med. 2022 Mar 14;11(6):1597.
Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014 Mar;175(3):408–18.
Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord [Internet]. 2018 Jan 1 [cited 2024 Feb 16];11:1756285617749134. Available from: https://doi.org/10.1177/1756285617749134
Li Y, Yang S, Dong X, Li Z, Peng Y, Jin W, et al. Factors affecting minimal manifestation status induction in myasthenia gravis. Ther Adv Neurol Disord [Internet]. 2022 Jan 1 [cited 2024 Feb 18];15:17562864221080520. Available from: https://doi.org/10.1177/17562864221080520
van Gaal SC, English SW, Bourque PRJ, Zwicker JC. Pulmonary Function Testing in Elderly Patients Treated for a Myasthenia Gravis Exacerbation. The Neurohospitalist [Internet]. 2019 Apr 1 [cited 2024 Feb 18];9(2):79–84. Available from: https://doi.org/10.1177/1941874418811249
Narita T, Nakane S, Nagaishi A, Minami N, Niino M, Kawaguchi N, et al. Immunotherapy for ocular myasthenia gravis: an observational study in Japan. Ther Adv Neurol Disord [Internet]. 2023 Jan 1 [cited 2024 Feb 18];16:17562864231163819. Available from: https://doi.org/10.1177/17562864231163819
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve [Internet]. 2019 Jul [cited 2024 Feb 16];60(1):14–24. Available from: https://onlinelibrary.wiley.com/doi/10.1002/mus.26447
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med [Internet]. 2016 Aug 11 [cited 2024 Feb 16];375(6):511–22. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1602489
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
